Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking
Exploring protein-protein interactions using the Site-Identification by Ligand Competitive Saturation (SILCS) methodology
No opportunities available
SilcsBio has no job openings at this time. Please check back again.
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design
SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software
FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio) announced today the issuance of a US patent covering key elements of SilcsBio’s drug design software. The SilcsBio software is broadly used […]